BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins for chronic diseases and immune-therapies. It is a cutting-edge and mature solution for oral formulations, not only for peptides, but also small molecules, novel protein scaffolds, nucleotides, domain antibodies, vaccines, immunotherapies etc.
Our company focuses the development of our own products on
- treatment of chronic diseases, such as diabetes and inflammatory diseases, and
- mucosal immune-therapies, for instance in cancer, allergy treatments,and auto-immune diseases and development of oral vaccines.
In terms of diabetes, our lead molecule is an oral "biobetter" of exenatide (GLP-1) in type II diabetes. We are also exploring the use of low dose IL-2 for early onset juvenile type I diabetes. Low dose IL-2 in animal models has shown to balance Treg and Teff immune cells to reverse or prevent type I diabetes. Especially in children, having an oral therapy will make a difference.
Our platform can also improve peptide and protein products by developing new indications (eg. more "mild" indications versus the injectable form) especially for chronic conditions (for instance GLP-1 in obesity and pre-diabetes).
A second area of interest is immune-therapies, as sublingual administration allows for initiating the immune cascade in the buccal area and allows for targeting the lymphatic system directly.
We have some good data with IL-2 immunotherapy in RA, peanut allergy and some cancer models.
Sublingual administration can increase efficacy and/or reduce side-effects compared to administration by injection. Therefore we are interested to develop for instance oral vaccines, or for instance anti-IL23 in RA or psoriasis.
Because of the stability enhancing properties, our technology is also very promising to develop oral biologics and vaccines for third world countries, by :
- Reducing the need for a cold chain
- Preventing the risk of infections due to needle handling (e.g. HIV, HCV)
As such we can "broaden access" for patients in third world countries, which is an important goal for WHO.
Because of the specific properties of our technology, it is applicable to a broad range of molecules, as shown in the diagram below.